Alnylam Commits to Outlicensing RNAi IP with InterfeRx Program Introduction | GenomeWeb

Alnylam Pharmaceuticals took another step last week toward its publicly stated goal of making its RNA interference intellectual property available to other drug developers, announcing the launch of the InterfeRx licensing program.

According to the company, the program will facilitate the licensing to third parties the rights to develop RNAi therapeutics under Alnylam’s portfolio of issued and pending patents, and will be overseen by Vincent Miles, senior vice president of business development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.